



# Wound Care Innovations.

Empowering  
Solutions.

Antimicrobial ECM  
Bioengineered Living Cells  
Placental Allografts

# Antimicrobial ECM

Start with  
PuraPly®  
Antimicrobial  
for all wound types

PuraPly®AM  
Antimicrobial Wound Matrix

PuraPly®XT  
Extra Fenestrated  
Five-layer Antimicrobial Wound Matrix

## Puts you in immediate control of the healing environment

The advanced antimicrobial barriers help control  
bioburden between weekly debridements<sup>1-5</sup>

### POWERFUL UNIQUE COMBINATION

- Native, cross-linked ECM + broad-spectrum PHMB acts as a bridge between weekly debridements by providing a sustained antimicrobial barrier effect<sup>1-5</sup>

### EARLY BIOBURDEN MANAGEMENT

- The PuraPly® Antimicrobial product line is the optimal foundation of care following sharp debridement to control bioburden and prevent biofilm re-formation<sup>6-8</sup>

### SUPPORTS HEALING

- In real-world clinical studies, PuraPly® AM demonstrated a decrease in wound size, reduction in time to closure, and an increase in observed granulation tissue<sup>9,10</sup>

### ELIMINATES THE NEED FOR AT-HOME PRIMARY DRESSING CHANGES

- Patient adherence improves when treatments require less intervention<sup>11</sup>

### PRODUCT FEATURES

PuraPly®AM  
Antimicrobial Wound Matrix

Two layers of native, cross-linked ECM<sup>1</sup>

Expanding clinical evidence in a variety  
of acute and chronic wounds<sup>9,10</sup>

Multiple sizes available

PuraPly®XT  
Extra Fenestrated  
Five-layer Antimicrobial Wound Matrix

Five layers of native, cross-linked ECM<sup>2</sup>

Thicker ECM maximizes surface area for  
PHMB saturation<sup>2,7,13</sup>

A higher number of fenestrations compared  
to PuraPly AM<sup>1,2</sup>



### BRIDGE BETWEEN WEEKLY DEBRIDEMENT<sup>12</sup>



# Bioengineered Living Cells


For stalled  
VLUs and DFUs

**Apligraf®**

Living Cellular Skin Substitute

## Innovation that remains ahead of its time

The biotech healer for stalled  
venous leg ulcers (VLUs) and  
diabetic foot ulcers (DFUs)



### BIOENGINEERED WITH LIVING CELLS

- Apligraf® looks, functions, and responds like healthy human skin<sup>14-17</sup>
- The cells of Apligraf are bioactive and poised to heal<sup>15,18</sup>

### TRANSFORMS WOUNDS FROM CHRONIC TO ACUTE

- Apligraf activates the patient's cells and helps regulate and correct growth factor signaling<sup>19,20</sup>
- Apligraf helps restore normal healing functions, putting wounds back on track to heal<sup>15,18,19,21</sup>

### BACKED BY UNMATCHED CLINICAL PROOF

- Extensive studies have demonstrated time and again Apligraf's ability to heal more VLUs and DFUs faster<sup>14,22-27</sup>
- Only Apligraf has conducted randomized controlled trials (RCTs) resulting in FDA approval for VLUs and DFUs<sup>14</sup>


### PROVEN TO BE COST-EFFECTIVE

- Helps to reduce VLU and DFU burden on patients and healthcare costs<sup>28-31</sup>

### UNSURPASSED ACCESS FOR PATIENTS

- 100% of Medicare contractors and commercial medical policies cover Apligraf treatment for VLUs and DFUs

### APLIGRAF HEALED



# Placental Allografts

For all stalled  
wound types

**Affinity**<sup>®</sup>  
Fresh Amniotic Membrane

## Living cells. Fresh solution.

Affinity<sup>®</sup> is the only fresh amniotic membrane wound covering<sup>32-34</sup> and has been shown to help move wounds from stalled to closed<sup>35</sup>

### CLOSEST CHOICE TO NATIVE AMNIOTIC MEMBRANE

- Affinity uses a gentle, proprietary process, AlloFresh™, that preserves the product in its fresh state and retains its native tissue characteristics<sup>32,33,36-38</sup>

### OPTIMAL TISSUE COMPOSITION

Never frozen or dehydrated, Affinity retains:

- Viable endogenous cells, including epithelial cells and fibroblasts<sup>33,36</sup>
- Growth factors and cytokines<sup>33,39</sup>
- Native extracellular matrix (ECM) proteins<sup>33,37,38</sup>
- Spongy layer<sup>33</sup>

### CLINICAL DATA IN RANDOMIZED CONTROLLED TRIAL AND REAL-WORLD SETTINGS

- As a protective wound covering, Affinity has been shown to support healing in a variety of wound types<sup>35,40-42</sup>

Note: Affinity is intended for use as a wound covering and barrier.



**NuShield**<sup>®</sup>  
Sterilized, Dehydrated Placental Allograft

## The most complete dehydrated placental allograft wound covering<sup>37,43</sup>

Convenience without compromise  
to support an optimal environment  
for healing



### COMPLETE LAYERS SET NuSHIELD APART

- NuShield<sup>®</sup> is a shelf-stable, dehydrated placental allograft wound covering that undergoes a unique preservation method and retains all layers of the placental membrane, including the spongy layer<sup>43,44</sup>

### RETAINS GROWTH FACTORS AND CYTOKINES<sup>43,45,46</sup>

- Following processing, analytical testing identified 640 components (growth factors, cytokines, and chemokines) that are retained in NuShield<sup>46</sup>

### CLINICAL DATA

- As a protective wound covering and in real-world patients, NuShield has been shown to support a favorable environment for healing in a variety of wound types and sizes<sup>47</sup>

Note: NuShield is intended for use as a wound covering and barrier.





## Addressing Wounds From Head to Toe With Innovative Solutions\*

Native, Cross-linked  
ECM + Broad-spectrum  
PHMB Antimicrobial Barriers

**PuraPly<sup>®</sup>AM**

Antimicrobial Wound Matrix

**PuraPly<sup>®</sup>XT**  
Extra Fenestrated

Five-layer Antimicrobial Wound Matrix


Fresh & Dehydrated  
Placental Allograft  
Wound Coverings

**Affinity<sup>®</sup>**

Fresh Amniotic Membrane

**NuShield<sup>®</sup>**

Sterilized, Dehydrated Placental Allograft



Bioengineered  
Living Cells<sup>†</sup>

**Apligraf<sup>®</sup>**

Living Cellular Skin Substitute

\* Organogenesis offers a variety of innovative products for wound care that are FDA PMA approved, 510(k) cleared, or are marketed under Section 361 of the Public Health Service Act as HCT/PS.

† Apligraf is approved for the treatment of VLU and DFUs.

Organogenesis is a leader in wound healing and for over 20 years has provided innovative solutions to help empower clinicians.

[www.organogenesis.com](http://www.organogenesis.com)

Organogenesis' Circle of Care is a comprehensive program that provides the highest-quality customer service and reimbursement support, with a wide range of expertise that includes benefits verification, information on ordering and shipping, and details on coding.



#### References

1. PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis Inc; 2020.
2. PuraPly XT Extra Fenestrated [package insert]. Canton, MA: Organogenesis Inc.
3. Data on file. PDR-0001. Organogenesis Inc.
4. Data on file. PDR-0002. Organogenesis Inc.
5. Data on file. PDR-0003. Organogenesis Inc.
6. Hübner NO, et al. *Skin Pharmacol Physiol*. 2010;23(1 suppl):17-27.
7. Brantley J, et al. *Wounds Int*. 2016;7(3):1-5.
8. Gilbert P, et al. *J Appl Microbiol*. 2005;99(4):703-715.
9. Oropallo AR. *Plast Reconstr Surg Glob Open*. 2019;7:e2047.
10. Bain MA, et al. *Plast Reconstr Surg Glob Open*. 2019;7(6):e2251.
11. Atreja A, et al. *MedGenMed*. 2005;7(1):4.
12. Davis SC, et al. *Int Wound J*. 2021;1-14. <https://doi.org/10.1111/iwj.13600>.
13. Carpenter S, et al. *Wounds*. 2016;28(6 suppl):S1-S20.
14. Apligraf [package insert]. Canton, MA: Organogenesis Inc; 2017.
15. Milstone LM, et al. *Wounds*. 2000;12(5 suppl A):12A-19A.
16. Schmid P. *Wounds*. 2000;12(5 Suppl A):4A-11A.
17. Carlson M, et al. *Tissue Eng Part A*. 2011;17(3-4):487-493.
18. Falanga V, et al. *J Invest Dermatol*. 2002;119(3):653-660.
19. Stone RC, et al. *Sci Transl Med*. 2017;9(371).doi:10.1126/scitranslmed.aaf8611.
20. Stone RC, et al. *Wound Repair Regen*. 2020;28:164-176.
21. Brem H, et al. *Surg Technol Int*. 2003;11:23-31.
22. Marston WA, et al. *Wound Repair Regen*. 2014;22(3):334-340.
23. Treadwell T, et al. *Adv Wound Care*. 2018;7(3):69-76.
24. Sabolinski ML, et al. *J Comp Eff Res*. 2018;7(8):797-805.
25. Veves A, et al. *Diabetes Care*. 2001;24(2):290-295.
26. Kirsner RS, et al. *Wound Repair Regen*. 2015;23(5):737-744.
27. Data on file. Organogenesis Inc.
28. Rice JB, et al. *J Med Econ*. 2014;17(5):347-356.
29. Barshes NR, et al. *Diabet Foot Ankle*. 2013;4.doi:10.3402/dfa.v4i0.21847.
30. Schonfeld WH, et al. *Wound Repair Regen*. 2000;8(4):251-257.
31. Rice JB, et al. *J Med Econ*. 2015;18(8):586-595.
32. Data on file. DR-0005. Organogenesis Inc.
33. McQuilling JP, et al. *Int Wound J*. 2017;14(6):993-1005.
34. Affinity Allograft Tissue Information and Instructions for Use. Canton, MA: Organogenesis Inc; 2021.
35. Serena TE, et al. *J Comp Eff Res*. 2020;9(1):23-34.
36. Data on file. DR-0008. Organogenesis Inc.
37. Niknejad H, et al. *Eur Cells Mater*. 2008;15:88-99.
38. Mamede AC, et al. *Cell Tissue Res*. 2012;349(2):447-458.
39. Data on file. DR-0007. Organogenesis Inc.
40. Sabo M, et al. *Chronic Wound Care Manage Res*. 2018;5:1-4.
41. Lambert CJ, et al. Poster presented at: Symposium on Advanced Wound Care Fall 2015; September 26-28, 2015; Las Vegas, NV.
42. Carpenter S, et al. Poster presented at: 4th Annual Innovations in Wound Healing Conference; December 7-10, 2017; Bimini, Bahamas.
43. McQuilling JP, et al. *Int Wound J*. 2019;16(3):827-840.
44. Data on file. Description of BioLoc Process. Organogenesis Inc.
45. Data on file. DR-0004. Organogenesis Inc.
46. McQuilling JP, et al. *Wound Repair Regen*. 2019;27(6):609-621.
47. Caporusso J, et al. *Wounds*. 2019;31(4 Suppl):S19-S27.